{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228639","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-05-18T18:15:14+00:00","discovered_at":"2026-05-18T18:16:00.286147+00:00","generated_at":"2026-05-18T18:16:58.552510+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx shareholders OK 14.5M-share equity plan; re-elect directors","bullets":["Third Amended and Restated 2023 Incentive Plan approved; up to 14.5M new shares available plus shares from prior plans.","Emil Kakkis, Shehnaaz Suliman, Daniel G. Welch re-elected as Class I directors to serve until 2029 Annual Meeting.","Ernst & Young ratified as independent auditor; advisory 'say-on-pay' proposal passed with 70.9M votes for.","Director compensation limit set at $900k per year ($1.5M for first year or Chair/Lead Director)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228639","json":"https://secwatch.observer/filing/0001193125-26-228639.json","markdown":"https://secwatch.observer/filing/0001193125-26-228639.md","text":"https://secwatch.observer/filing/0001193125-26-228639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/rare-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:16:58.552510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03b20dc55b5895b295433f0f21eba4c276edea03","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-05-14 meeting.","evidence_excerpt":"Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes on Proposal 3 were as follows: Votes For Votes Against Abstentions 84,551,399 221,802 13,187","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"11a50b0e83cc920188b9aa2642e3d777c565a556","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Approval of the Third A&R 2023 Plan at the 2026-05-14 meeting.","evidence_excerpt":"Proposal No. 2 – Approval of the Third A&R 2023 Plan At the Annual Meeting, the Company’s stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 50,659,150 22,888,600 26,748 11,211,890","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"876a061bb407276d0bc8d542eaf69845a53a5ba1","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Election of Class I Directors at the 2026-05-14 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 72,517,613 1,056,885 11,211,890 Shehnaaz Suliman, M.D. 65,801,638 7,772,860 11,211,890 Daniel G. Welch 66,301,426 7,273,072 11,211,890","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"c27d46c6485edb1cccdc604fe5cbf957745a1ee6","claim":"Ultragenyx Pharmaceutical Inc. shareholders approved Advisory (Non-Binding) Vote to Approve Executive Compensation at the 2026-05-14 meeting.","evidence_excerpt":"Proposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 4 were as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,945,277 2,594,517 34,704 11,211,890","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526228639/0001193125-26-228639-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}